IL2 and neoplasm: To test this, we first confirmed that GSDMD deficiency in T cells, and its inactivation by DSF treatment, both decreased the IL-2 levels in the TME of multiple tumor models, regardless of the presence or absence of CD8+ T cells (Figure 4, B–E, and Supplemental Figure 4, D–G).